FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). Efficacy was evaluated in Study ML39345 (NCT03141684), an open-label, single-arm study in 49 adult and pediatric patients with unresectable or […]
Phase 2 Clinical Trial for Alveolar Soft Part Sarcoma Patients: Testing Atezolizumab, A Study by the NCI
Dear ASPS community, please read the recent update of this clinical trial from September 2020: This is a Phase II clinical study testing the ability of the anti-PD-L1 antibody, Atezolizumab, in treating patients with ASPS that has spread to other parts of the body and cannot be removed by surgery. The FDA granted Breakthrough Therapy Designation […]
Progress Reports on Alveolar Soft Part Sarcoma from the ASCO 2018 Meeting
The American Society of Clinical Oncology (ASCO) annual meeting took place this year in Chicago between June 1-5, 2018 Here are eight Alveolar Soft Part Sarcoma (ASPS) related abstracts from the meeting. Of these, seven describing results of clinical trials with the following treatments: Phase III of Anlotinib Phase II trial of Axitinib plus pembrolizumab […]
Update on Alveolar Soft Part Sarcoma Clinical and Preclinical Studies as Presented at the Annual Meeting of CTOS in November 8-11, 2017
Below are summaries of three clinical studies and one preclinical study on Alveolar Soft Part Sarcoma as were presented at the 2017 annual meeting of the “Connective Tissue Oncology Society” (CTOS) in November 8-11. Please click the titles of each one of the 3 clinical studies to read more information on the “clinical Trials.gov” website. […]
New ASPS Trial: APROMISS – A Phase III Trial of Anlotinib for Patients with Alveolar Soft Part Sarcoma and Other Sarcomas
OPEN NOW: APROMISS – A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Sponsored by: Advenchen Laboratories, LLC. ClinicalTrials.gov Identifier: NCT03016819 Anlotinib (AL3818), a tyrosine kinase inhibitor, is an investigational drug being evaluated in the treatment of Alveolar Soft Part Sarcoma […]
Anlotinib Shows Efficacy in ASPS Patients in Phase II Study in China
A presentation is the recent annual meeting of the American Society of Clinical Oncology (ASCO) conference in Chicago highlighted the new drug Anlotinib and its efficacy in treating Alveolar Soft Part Sarcoma patients. Anlotinib is a new receptor tyrosine kinase inhibitor, currently in phase II clinical trials in China. Patients with different types of soft […]
New ASPS Clinical Trial: Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
New clinical trial for ASPS is expected to open on March 2016. Study number: NCT02636725 This is a phase II clinical trial that combines treatment with Axitinib and Pembrolizumab in patients with advanced Alveolar Soft Part Sarcoma (ASPS) and other soft tissue sarcomas. Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor. […]
Important Announcement: CASPS – A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma
OPEN NOW: CASPS – A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma Sponsored by: The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust Information provided by: The Institute of Cancer Research – Clinical Trials and Statistics Unit ClinicalTrials.gov Identifier: NCT01337401 Cediranib (AZD2171) is a […]
A Summary of Phase II Cederanib Clinical Trial
The summary of the phase 2 clinical trial of Cediranib on Alveolar Soft Part Sarcoma was recently published in the “Journal of Clinical Oncology” by Shivaani Kummar and others from the National Cancer Institute and the Frederick National Laboratory for Cancer Research. The authors report that Cediranib has substantial single-agent activity, producing an objective response […]
Update on the Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
If you consider to join the following clinical trial: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma ; study NCT01391962 Please note that patients can join only if: · Patients show evidence of disease progression · Patients must not have received prior treatment with any VEGF receptor tyrosine kinase inhibitor (e.g., cediranib, sunitinib, pazopanib, sorafenib); […]